Abzena PLC Issue of Ordinary Shares (5013J)
March 29 2018 - 12:34PM
UK Regulatory
TIDMABZA
RNS Number : 5013J
Abzena PLC
29 March 2018
Abzena plc
Issue of Ordinary Shares
Cambridge, UK, 29 March 2018 - Abzena plc (AIM: ABZA, 'Abzena'
or the 'Group'), a life sciences group providing services and
technologies to enable development and manufacture of
biopharmaceutical products, announces that the Group has today
issued 403,269 new ordinary shares of GBP0.002 each ('Ordinary
Shares').
The Ordinary Shares were issued following the completion of the
final vesting period of the restricted stock units issued to
employees on the acquisition of The Chemical Research Solution LLC
(known as 'TCRS') in December 2015 and the acquisition of
PacificGMP in September 2015.
The new Ordinary Shares rank pari passu with the Company's
existing issued ordinary shares. Application has been made for
admission of the Ordinary Shares to trading on AIM, which is
expected to occur at 8.00am on or around 6 April 2018.
Following Admission, the Company's enlarged issued share capital
will comprise 214,220,399 ordinary shares of GBP0.002 each with
voting rights. No shares are held in Treasury. The total number of
voting rights in the Company is therefore 214,220,399. The figure
of 214,220,399 ordinary shares may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black +44 20 7260
/ Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners (PR advisors) +44 20 7457
Melanie Toyne Sewell / Alex 2020
Shaw abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Biology research studies, including immunogenicity assessment
of candidate biopharmaceutical products and bioassay
development;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development;
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads; and.
-- GMP analytical services for biopharmaceutical manufacturing projects
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOELLFVRVFIAFIT
(END) Dow Jones Newswires
March 29, 2018 12:34 ET (16:34 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024